Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers

Khoshghamat, Negar, Jafari, Niloufar, Moetamani-Ahmadi, Mehrdad, Khalili-Tanha, Ghazaleh, Khajavi rad, Mohammad-Hossein, Sahebdel, Saeed, Khalili-Tanha, Nima, Soleimanpour, Saman, Khazaei, Majid, Hassanian, Seyed Mahdi, Ferns, Gordon A and Avan, Amir (2021) Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers. Pathology - Research and Practice, 220. a153390 1-6. ISSN 0344-0338

[img] PDF - Accepted Version
Restricted to SRO admin only until 19 February 2022.
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (397kB)

Abstract

Gastrointestinal (GIs) cancers are among the most common causes of cancer related death, and hence the importance for the identification of novel prognostic/predictive biomarkers for detection of patients at an early stage, and for using these to identify novel targeted therapies to improve the efficacy of existing chemotherapeutic regimens. Programmed cell death 1 has been reported as a potential target in several malignancies, and targeting agents are being developed, some already approved by FDA, such as: pembrolizumab, Atezolizumab, Nivolumab. Pembrolizumab that have been approved for the treatment of metastatic non-small cell lung cancer. Here we provide an overview of the mechanism of action PD-1/PD-L1, prognostic value and current progress in clinical trials using PD-1/PD-L1 inhibitors, and the resistant mechanisms at underlie the inhibitory effect of these agents in the treatment of gastrointestinal cancers.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Division of Medical Education
SWORD Depositor: Mx Elements Account
Depositing User: Mx Elements Account
Date Deposited: 08 Apr 2021 07:08
Last Modified: 08 Apr 2021 07:15
URI: http://sro.sussex.ac.uk/id/eprint/98162

View download statistics for this item

📧 Request an update